ZA200601485B - Phenoxiacetic acid derivatives - Google Patents
Phenoxiacetic acid derivatives Download PDFInfo
- Publication number
- ZA200601485B ZA200601485B ZA200601485A ZA200601485A ZA200601485B ZA 200601485 B ZA200601485 B ZA 200601485B ZA 200601485 A ZA200601485 A ZA 200601485A ZA 200601485 A ZA200601485 A ZA 200601485A ZA 200601485 B ZA200601485 B ZA 200601485B
- Authority
- ZA
- South Africa
- Prior art keywords
- chloro
- phenoxy
- phenyl
- methylsulfonyl
- acetic acid
- Prior art date
Links
- 239000002253 acid Substances 0.000 title claims description 36
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Natural products CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 78
- 150000001875 compounds Chemical class 0.000 claims description 73
- 229910052736 halogen Inorganic materials 0.000 claims description 50
- 229910052739 hydrogen Inorganic materials 0.000 claims description 46
- 150000002367 halogens Chemical group 0.000 claims description 45
- 239000001257 hydrogen Substances 0.000 claims description 45
- 125000000217 alkyl group Chemical group 0.000 claims description 42
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 40
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 36
- 125000001424 substituent group Chemical group 0.000 claims description 33
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 29
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 28
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 22
- 235000019260 propionic acid Nutrition 0.000 claims description 22
- 125000005843 halogen group Chemical group 0.000 claims description 21
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 21
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims description 21
- 238000006243 chemical reaction Methods 0.000 claims description 19
- 239000000203 mixture Substances 0.000 claims description 19
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 claims description 18
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 17
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 17
- 125000001153 fluoro group Chemical group F* 0.000 claims description 17
- 125000001072 heteroaryl group Chemical group 0.000 claims description 16
- 150000003839 salts Chemical class 0.000 claims description 16
- 125000003118 aryl group Chemical group 0.000 claims description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
- 229910052760 oxygen Inorganic materials 0.000 claims description 14
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims description 13
- 201000010099 disease Diseases 0.000 claims description 12
- 239000012453 solvate Substances 0.000 claims description 10
- -1 OR’ and NR°R’ Inorganic materials 0.000 claims description 9
- 125000003342 alkenyl group Chemical group 0.000 claims description 9
- 125000006239 protecting group Chemical group 0.000 claims description 8
- 125000000304 alkynyl group Chemical group 0.000 claims description 7
- 229910052799 carbon Inorganic materials 0.000 claims description 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 7
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 7
- 125000004429 atom Chemical group 0.000 claims description 6
- 229910052792 caesium Inorganic materials 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 6
- 206010039083 rhinitis Diseases 0.000 claims description 6
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 6
- 208000006673 asthma Diseases 0.000 claims description 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 5
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 5
- 229910052757 nitrogen Inorganic materials 0.000 claims description 5
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 4
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 4
- 102000005962 receptors Human genes 0.000 claims description 4
- 108020003175 receptors Proteins 0.000 claims description 4
- 229920006395 saturated elastomer Polymers 0.000 claims description 4
- 229910052717 sulfur Inorganic materials 0.000 claims description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 4
- XPOUWICLOLTBKH-SNVBAGLBSA-N (2r)-2-[4-chloro-2-(4-methylsulfonylphenyl)sulfanylphenoxy]propanoic acid Chemical compound OC(=O)[C@@H](C)OC1=CC=C(Cl)C=C1SC1=CC=C(S(C)(=O)=O)C=C1 XPOUWICLOLTBKH-SNVBAGLBSA-N 0.000 claims description 3
- IGGJVDVYSKYZKT-UHFFFAOYSA-N 2-(4-chloro-2-quinolin-3-yloxyphenoxy)acetic acid Chemical compound OC(=O)COC1=CC=C(Cl)C=C1OC1=CN=C(C=CC=C2)C2=C1 IGGJVDVYSKYZKT-UHFFFAOYSA-N 0.000 claims description 3
- MBBBUWIKGWSTAO-UHFFFAOYSA-N 2-[2-(2-chloro-4-ethylsulfonylphenoxy)-4-fluorophenoxy]acetic acid Chemical compound ClC1=CC(S(=O)(=O)CC)=CC=C1OC1=CC(F)=CC=C1OCC(O)=O MBBBUWIKGWSTAO-UHFFFAOYSA-N 0.000 claims description 3
- UGMFVRAEYTYCPF-UHFFFAOYSA-N 2-[2-(2-chloro-4-ethylsulfonylphenyl)sulfanyl-4-fluorophenoxy]acetic acid Chemical compound ClC1=CC(S(=O)(=O)CC)=CC=C1SC1=CC(F)=CC=C1OCC(O)=O UGMFVRAEYTYCPF-UHFFFAOYSA-N 0.000 claims description 3
- YVWIJOUCWQAOKM-UHFFFAOYSA-N 2-[2-(2-chloro-4-methylsulfonylphenoxy)-4,5-difluorophenoxy]acetic acid Chemical compound ClC1=CC(S(=O)(=O)C)=CC=C1OC1=CC(F)=C(F)C=C1OCC(O)=O YVWIJOUCWQAOKM-UHFFFAOYSA-N 0.000 claims description 3
- HABMSFJEZJYHMJ-UHFFFAOYSA-N 2-[2-(2-chloro-4-methylsulfonylphenoxy)-4-(trifluoromethyl)phenoxy]butanoic acid Chemical compound CCC(C(O)=O)OC1=CC=C(C(F)(F)F)C=C1OC1=CC=C(S(C)(=O)=O)C=C1Cl HABMSFJEZJYHMJ-UHFFFAOYSA-N 0.000 claims description 3
- DXFBCSWUKZIYDP-UHFFFAOYSA-N 2-[2-(2-chloro-4-methylsulfonylphenoxy)-4-fluorophenoxy]-2-methylpropanoic acid Chemical compound OC(=O)C(C)(C)OC1=CC=C(F)C=C1OC1=CC=C(S(C)(=O)=O)C=C1Cl DXFBCSWUKZIYDP-UHFFFAOYSA-N 0.000 claims description 3
- JTUSETDYFVBGCR-UHFFFAOYSA-N 2-[2-(2-chloro-4-methylsulfonylphenoxy)phenoxy]acetic acid Chemical compound ClC1=CC(S(=O)(=O)C)=CC=C1OC1=CC=CC=C1OCC(O)=O JTUSETDYFVBGCR-UHFFFAOYSA-N 0.000 claims description 3
- ZUWRUWDEYPSFBL-UHFFFAOYSA-N 2-[2-(2-chloro-4-methylsulfonylphenyl)sulfanyl-4-fluorophenoxy]-2-methylpropanoic acid Chemical compound OC(=O)C(C)(C)OC1=CC=C(F)C=C1SC1=CC=C(S(C)(=O)=O)C=C1Cl ZUWRUWDEYPSFBL-UHFFFAOYSA-N 0.000 claims description 3
- UBLYUSFUHDOYHN-UHFFFAOYSA-N 2-[4-chloro-2-(2-chloro-4-ethylsulfonylphenoxy)phenoxy]acetic acid Chemical compound ClC1=CC(S(=O)(=O)CC)=CC=C1OC1=CC(Cl)=CC=C1OCC(O)=O UBLYUSFUHDOYHN-UHFFFAOYSA-N 0.000 claims description 3
- BOUMNJZRBSZUDN-UHFFFAOYSA-N 2-[4-chloro-2-(2-chloro-4-ethylsulfonylphenyl)sulfanylphenoxy]acetic acid Chemical compound ClC1=CC(S(=O)(=O)CC)=CC=C1SC1=CC(Cl)=CC=C1OCC(O)=O BOUMNJZRBSZUDN-UHFFFAOYSA-N 0.000 claims description 3
- LQCYYTFHZPEXAT-UHFFFAOYSA-N 2-[4-chloro-2-(2-chloro-4-methylsulfonylphenoxy)phenoxy]acetic acid Chemical compound ClC1=CC(S(=O)(=O)C)=CC=C1OC1=CC(Cl)=CC=C1OCC(O)=O LQCYYTFHZPEXAT-UHFFFAOYSA-N 0.000 claims description 3
- WHYIHUSSUFKTBZ-UHFFFAOYSA-N 2-[4-chloro-2-(2-chloro-4-methylsulfonylphenyl)sulfanylphenoxy]-2-methylpropanoic acid Chemical compound OC(=O)C(C)(C)OC1=CC=C(Cl)C=C1SC1=CC=C(S(C)(=O)=O)C=C1Cl WHYIHUSSUFKTBZ-UHFFFAOYSA-N 0.000 claims description 3
- QRQZNGXNIKSCPW-UHFFFAOYSA-N 2-[4-chloro-2-(2-chloro-4-methylsulfonylphenyl)sulfanylphenoxy]acetic acid Chemical compound ClC1=CC(S(=O)(=O)C)=CC=C1SC1=CC(Cl)=CC=C1OCC(O)=O QRQZNGXNIKSCPW-UHFFFAOYSA-N 0.000 claims description 3
- UUCMUZNLQKZMOG-UHFFFAOYSA-N 2-[4-chloro-2-(2-chloro-n-methyl-4-methylsulfonylanilino)phenoxy]acetic acid Chemical compound C=1C(Cl)=CC=C(OCC(O)=O)C=1N(C)C1=CC=C(S(C)(=O)=O)C=C1Cl UUCMUZNLQKZMOG-UHFFFAOYSA-N 0.000 claims description 3
- YVBCTEDNWTUIHB-UHFFFAOYSA-N 2-[4-chloro-2-(4-methylsulfonylanilino)phenoxy]acetic acid Chemical compound C1=CC(S(=O)(=O)C)=CC=C1NC1=CC(Cl)=CC=C1OCC(O)=O YVBCTEDNWTUIHB-UHFFFAOYSA-N 0.000 claims description 3
- OOUJECDNSYKLLO-UHFFFAOYSA-N 2-[4-chloro-2-(4-methylsulfonylphenoxy)phenoxy]acetic acid Chemical compound C1=CC(S(=O)(=O)C)=CC=C1OC1=CC(Cl)=CC=C1OCC(O)=O OOUJECDNSYKLLO-UHFFFAOYSA-N 0.000 claims description 3
- CKMHCINAXMIZBD-UHFFFAOYSA-N 2-[4-chloro-2-(4-methylsulfonylphenyl)sulfanylphenoxy]acetic acid Chemical compound C1=CC(S(=O)(=O)C)=CC=C1SC1=CC(Cl)=CC=C1OCC(O)=O CKMHCINAXMIZBD-UHFFFAOYSA-N 0.000 claims description 3
- GHFLOZJXCILUDU-UHFFFAOYSA-N 2-[4-chloro-2-(5-chloropyridin-2-yl)sulfanylphenoxy]acetic acid Chemical compound OC(=O)COC1=CC=C(Cl)C=C1SC1=CC=C(Cl)C=N1 GHFLOZJXCILUDU-UHFFFAOYSA-N 0.000 claims description 3
- JGLGXIQLWBSOPQ-UHFFFAOYSA-N 2-[4-chloro-2-[4-(methylcarbamoyl)phenyl]sulfanylphenoxy]acetic acid Chemical compound C1=CC(C(=O)NC)=CC=C1SC1=CC(Cl)=CC=C1OCC(O)=O JGLGXIQLWBSOPQ-UHFFFAOYSA-N 0.000 claims description 3
- QMXBCUSSRNIFCR-UHFFFAOYSA-N 2-[4-chloro-2-[4-methylsulfonyl-3-(trifluoromethyl)phenoxy]phenoxy]acetic acid Chemical compound C1=C(C(F)(F)F)C(S(=O)(=O)C)=CC=C1OC1=CC(Cl)=CC=C1OCC(O)=O QMXBCUSSRNIFCR-UHFFFAOYSA-N 0.000 claims description 3
- 230000009286 beneficial effect Effects 0.000 claims description 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 3
- 125000004185 ester group Chemical group 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 125000004076 pyridyl group Chemical group 0.000 claims description 3
- 238000002560 therapeutic procedure Methods 0.000 claims description 3
- RARNYMRRZAWUGS-JTQLQIEISA-N (2s)-2-[4-chloro-2-(4-methylsulfonylphenoxy)phenoxy]propanoic acid Chemical compound OC(=O)[C@H](C)OC1=CC=C(Cl)C=C1OC1=CC=C(S(C)(=O)=O)C=C1 RARNYMRRZAWUGS-JTQLQIEISA-N 0.000 claims description 2
- XPOUWICLOLTBKH-JTQLQIEISA-N (2s)-2-[4-chloro-2-(4-methylsulfonylphenyl)sulfanylphenoxy]propanoic acid Chemical compound OC(=O)[C@H](C)OC1=CC=C(Cl)C=C1SC1=CC=C(S(C)(=O)=O)C=C1 XPOUWICLOLTBKH-JTQLQIEISA-N 0.000 claims description 2
- TYMFZLFJVYQHJK-UHFFFAOYSA-N 2-(2-benzyl-4-methylphenoxy)acetic acid Chemical compound CC1=CC=C(OCC(O)=O)C(CC=2C=CC=CC=2)=C1 TYMFZLFJVYQHJK-UHFFFAOYSA-N 0.000 claims description 2
- AGKUAKMXGRVSSP-UHFFFAOYSA-N 2-(4-chloro-2-hydroxyphenoxy)-2-methylpropanoic acid Chemical compound OC(=O)C(C)(C)OC1=CC=C(Cl)C=C1O AGKUAKMXGRVSSP-UHFFFAOYSA-N 0.000 claims description 2
- VEWYELIASXTVRO-UHFFFAOYSA-N 2-(4-fluoro-2-hydroxyphenoxy)acetic acid Chemical compound OC(=O)COC1=CC=C(F)C=C1O VEWYELIASXTVRO-UHFFFAOYSA-N 0.000 claims description 2
- CIOFTFQCOATEJS-UHFFFAOYSA-N 2-[2-(2-chloro-4-ethylsulfonylanilino)-4-fluorophenoxy]-2-methylpropanoic acid Chemical compound ClC1=CC(S(=O)(=O)CC)=CC=C1NC1=CC(F)=CC=C1OC(C)(C)C(O)=O CIOFTFQCOATEJS-UHFFFAOYSA-N 0.000 claims description 2
- GFPSZCWTXRMYBY-UHFFFAOYSA-N 2-[2-(2-chloro-4-ethylsulfonylphenyl)sulfanyl-4-(trifluoromethyl)phenoxy]acetic acid Chemical compound ClC1=CC(S(=O)(=O)CC)=CC=C1SC1=CC(C(F)(F)F)=CC=C1OCC(O)=O GFPSZCWTXRMYBY-UHFFFAOYSA-N 0.000 claims description 2
- UEZBNKZOFMZIKN-UHFFFAOYSA-N 2-[2-(2-chloro-4-methylsulfonylphenoxy)-4-fluorophenoxy]acetic acid Chemical compound ClC1=CC(S(=O)(=O)C)=CC=C1OC1=CC(F)=CC=C1OCC(O)=O UEZBNKZOFMZIKN-UHFFFAOYSA-N 0.000 claims description 2
- VTNPFXJTTSYULZ-UHFFFAOYSA-N 2-[2-(2-chloro-4-methylsulfonylphenyl)sulfanyl-4-fluorophenoxy]acetic acid Chemical compound ClC1=CC(S(=O)(=O)C)=CC=C1SC1=CC(F)=CC=C1OCC(O)=O VTNPFXJTTSYULZ-UHFFFAOYSA-N 0.000 claims description 2
- WTKOTNKDXKSMEB-UHFFFAOYSA-N 2-[2-[(4-ethylsulfonylphenyl)methyl]-4-(trifluoromethyl)phenoxy]acetic acid Chemical compound C1=CC(S(=O)(=O)CC)=CC=C1CC1=CC(C(F)(F)F)=CC=C1OCC(O)=O WTKOTNKDXKSMEB-UHFFFAOYSA-N 0.000 claims description 2
- RVCFZMTUSAMOPJ-UHFFFAOYSA-N 2-[4-chloro-2-(2-chloro-4-cyanophenyl)sulfanylphenoxy]acetic acid Chemical compound OC(=O)COC1=CC=C(Cl)C=C1SC1=CC=C(C#N)C=C1Cl RVCFZMTUSAMOPJ-UHFFFAOYSA-N 0.000 claims description 2
- KNKZIOAABKESLW-UHFFFAOYSA-N 2-[4-chloro-2-(2-chloro-4-methylsulfonylanilino)phenoxy]-2-methylpropanoic acid Chemical compound OC(=O)C(C)(C)OC1=CC=C(Cl)C=C1NC1=CC=C(S(C)(=O)=O)C=C1Cl KNKZIOAABKESLW-UHFFFAOYSA-N 0.000 claims description 2
- PIAAHYFALWUUPI-UHFFFAOYSA-N 2-[4-chloro-2-(2-chloro-4-methylsulfonylphenoxy)phenoxy]-2-methylpropanoic acid Chemical compound OC(=O)C(C)(C)OC1=CC=C(Cl)C=C1OC1=CC=C(S(C)(=O)=O)C=C1Cl PIAAHYFALWUUPI-UHFFFAOYSA-N 0.000 claims description 2
- HNUXVOMXQYGQQK-UHFFFAOYSA-N 2-[4-chloro-2-(2-methylsulfonylphenyl)sulfanylphenoxy]acetic acid Chemical compound CS(=O)(=O)C1=CC=CC=C1SC1=CC(Cl)=CC=C1OCC(O)=O HNUXVOMXQYGQQK-UHFFFAOYSA-N 0.000 claims description 2
- KYMFVCOUPCLCHE-UHFFFAOYSA-N 2-[4-chloro-2-(4-ethylsulfonylphenyl)sulfanylphenoxy]acetic acid Chemical compound C1=CC(S(=O)(=O)CC)=CC=C1SC1=CC(Cl)=CC=C1OCC(O)=O KYMFVCOUPCLCHE-UHFFFAOYSA-N 0.000 claims description 2
- PVEGPGIMLMOMHO-UHFFFAOYSA-N 2-[4-chloro-2-(4-methylsulfonylphenyl)sulfinylphenoxy]acetic acid Chemical compound C1=CC(S(=O)(=O)C)=CC=C1S(=O)C1=CC(Cl)=CC=C1OCC(O)=O PVEGPGIMLMOMHO-UHFFFAOYSA-N 0.000 claims description 2
- BEAWNVDIFYFJKR-UHFFFAOYSA-N 2-[4-chloro-2-(4-methylsulfonylphenyl)sulfonylphenoxy]acetic acid Chemical compound C1=CC(S(=O)(=O)C)=CC=C1S(=O)(=O)C1=CC(Cl)=CC=C1OCC(O)=O BEAWNVDIFYFJKR-UHFFFAOYSA-N 0.000 claims description 2
- ZLZUUMHBNNWTIF-UHFFFAOYSA-N 4-chloro-2-(2-chloro-4-methylsulfonylphenoxy)phenol Chemical compound ClC1=CC(S(=O)(=O)C)=CC=C1OC1=CC(Cl)=CC=C1O ZLZUUMHBNNWTIF-UHFFFAOYSA-N 0.000 claims description 2
- BUXDWRTYLCDDQG-UHFFFAOYSA-N 4-chloro-2-(2-chloro-4-methylsulfonylphenyl)sulfanylphenol Chemical compound ClC1=CC(S(=O)(=O)C)=CC=C1SC1=CC(Cl)=CC=C1O BUXDWRTYLCDDQG-UHFFFAOYSA-N 0.000 claims description 2
- VDJQCENKGJVBLS-UHFFFAOYSA-N 4-chloro-2-(4-ethylsulfonyl-2-methylphenyl)sulfanylphenol Chemical compound CC1=CC(S(=O)(=O)CC)=CC=C1SC1=CC(Cl)=CC=C1O VDJQCENKGJVBLS-UHFFFAOYSA-N 0.000 claims description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 claims description 2
- 150000001298 alcohols Chemical class 0.000 claims description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims description 2
- 230000003301 hydrolyzing effect Effects 0.000 claims description 2
- 230000003647 oxidation Effects 0.000 claims description 2
- 238000007254 oxidation reaction Methods 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 125000001174 sulfone group Chemical group 0.000 claims description 2
- 150000003568 thioethers Chemical class 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims 16
- 150000002431 hydrogen Chemical group 0.000 claims 9
- IEDDSVITIOMMBA-UHFFFAOYSA-N 2-[2-[2-chloro-4-(ethylsulfonylamino)phenoxy]-4-fluorophenoxy]acetic acid Chemical compound ClC1=CC(NS(=O)(=O)CC)=CC=C1OC1=CC(F)=CC=C1OCC(O)=O IEDDSVITIOMMBA-UHFFFAOYSA-N 0.000 claims 2
- DMWNJFGNKHRMJL-UHFFFAOYSA-N 2-[4,5-dichloro-2-(2-chloro-4-methylsulfonylphenoxy)phenoxy]acetic acid Chemical compound ClC1=CC(S(=O)(=O)C)=CC=C1OC1=CC(Cl)=C(Cl)C=C1OCC(O)=O DMWNJFGNKHRMJL-UHFFFAOYSA-N 0.000 claims 2
- WPDQQKXECYFDHI-UHFFFAOYSA-N 2-[4-chloro-2-(2-chloro-4-ethylsulfonylanilino)phenoxy]-2-methylpropanoic acid Chemical compound ClC1=CC(S(=O)(=O)CC)=CC=C1NC1=CC(Cl)=CC=C1OC(C)(C)C(O)=O WPDQQKXECYFDHI-UHFFFAOYSA-N 0.000 claims 2
- DQORQOAIMOXSAP-UHFFFAOYSA-N 2-[4-chloro-2-(2-chloro-4-ethylsulfonylanilino)phenoxy]acetic acid Chemical compound ClC1=CC(S(=O)(=O)CC)=CC=C1NC1=CC(Cl)=CC=C1OCC(O)=O DQORQOAIMOXSAP-UHFFFAOYSA-N 0.000 claims 2
- MWHCVLWDSWEWFL-UHFFFAOYSA-N 2-[4-chloro-2-(2-chloro-n-ethyl-4-methylsulfonylanilino)phenoxy]acetic acid Chemical compound C=1C(Cl)=CC=C(OCC(O)=O)C=1N(CC)C1=CC=C(S(C)(=O)=O)C=C1Cl MWHCVLWDSWEWFL-UHFFFAOYSA-N 0.000 claims 2
- ZMOGYSHKDHKEPG-VIFPVBQESA-N (2s)-2-[2-(2-chloro-4-methylsulfonylanilino)-4-fluorophenoxy]propanoic acid Chemical compound OC(=O)[C@H](C)OC1=CC=C(F)C=C1NC1=CC=C(S(C)(=O)=O)C=C1Cl ZMOGYSHKDHKEPG-VIFPVBQESA-N 0.000 claims 1
- DCNNIFYZFCCXNZ-JTQLQIEISA-N (2s)-2-[4-chloro-2-(2-chloro-4-ethylsulfonylphenoxy)phenoxy]propanoic acid Chemical compound ClC1=CC(S(=O)(=O)CC)=CC=C1OC1=CC(Cl)=CC=C1O[C@@H](C)C(O)=O DCNNIFYZFCCXNZ-JTQLQIEISA-N 0.000 claims 1
- HSLXQEAIKORKBC-JTQLQIEISA-N (2s)-2-[4-chloro-2-(2-chloro-4-ethylsulfonylphenyl)sulfanylphenoxy]propanoic acid Chemical compound ClC1=CC(S(=O)(=O)CC)=CC=C1SC1=CC(Cl)=CC=C1O[C@@H](C)C(O)=O HSLXQEAIKORKBC-JTQLQIEISA-N 0.000 claims 1
- IRHGWEOJANIAAG-VIFPVBQESA-N (2s)-2-[4-chloro-2-(2-chloro-4-methylsulfonylanilino)phenoxy]propanoic acid Chemical compound OC(=O)[C@H](C)OC1=CC=C(Cl)C=C1NC1=CC=C(S(C)(=O)=O)C=C1Cl IRHGWEOJANIAAG-VIFPVBQESA-N 0.000 claims 1
- BRFJGHZSNKHMLO-VIFPVBQESA-N (2s)-2-[4-chloro-2-(2-chloro-4-methylsulfonylphenyl)sulfanylphenoxy]propanoic acid Chemical compound OC(=O)[C@H](C)OC1=CC=C(Cl)C=C1SC1=CC=C(S(C)(=O)=O)C=C1Cl BRFJGHZSNKHMLO-VIFPVBQESA-N 0.000 claims 1
- UPCPHMDYJGAFEO-UHFFFAOYSA-N 2-(2-chloro-4-ethylsulfonylanilino)-4-(trifluoromethyl)phenol Chemical compound ClC1=CC(S(=O)(=O)CC)=CC=C1NC1=CC(C(F)(F)F)=CC=C1O UPCPHMDYJGAFEO-UHFFFAOYSA-N 0.000 claims 1
- XWAFEPIYNNYLAH-UHFFFAOYSA-N 2-(2-chloro-4-ethylsulfonylanilino)-4-fluorophenol Chemical compound ClC1=CC(S(=O)(=O)CC)=CC=C1NC1=CC(F)=CC=C1O XWAFEPIYNNYLAH-UHFFFAOYSA-N 0.000 claims 1
- IJJQCBCBONKWBM-UHFFFAOYSA-N 2-(2-chloro-4-methylsulfonylanilino)-4-(trifluoromethyl)phenol Chemical compound ClC1=CC(S(=O)(=O)C)=CC=C1NC1=CC(C(F)(F)F)=CC=C1O IJJQCBCBONKWBM-UHFFFAOYSA-N 0.000 claims 1
- UTKKCPFFKQBGIA-UHFFFAOYSA-N 2-(2-chloro-4-methylsulfonylanilino)-4-fluorophenol Chemical compound ClC1=CC(S(=O)(=O)C)=CC=C1NC1=CC(F)=CC=C1O UTKKCPFFKQBGIA-UHFFFAOYSA-N 0.000 claims 1
- BUNTTYGHKBRNIT-UHFFFAOYSA-N 2-(2-chloro-4-methylsulfonylphenyl)sulfanyl-4-(trifluoromethyl)phenol Chemical compound ClC1=CC(S(=O)(=O)C)=CC=C1SC1=CC(C(F)(F)F)=CC=C1O BUNTTYGHKBRNIT-UHFFFAOYSA-N 0.000 claims 1
- LVIQCCBIKCDGNC-UHFFFAOYSA-N 2-(4-chloro-2-quinolin-8-ylsulfanylphenoxy)acetic acid Chemical compound OC(=O)COC1=CC=C(Cl)C=C1SC1=CC=CC2=CC=CN=C12 LVIQCCBIKCDGNC-UHFFFAOYSA-N 0.000 claims 1
- KAGQFTKJGKFBGK-UHFFFAOYSA-N 2-[2-(2-chloro-4-ethylsulfonylanilino)-4-fluorophenoxy]acetic acid Chemical compound ClC1=CC(S(=O)(=O)CC)=CC=C1NC1=CC(F)=CC=C1OCC(O)=O KAGQFTKJGKFBGK-UHFFFAOYSA-N 0.000 claims 1
- JSOMLHMTXRHZQC-UHFFFAOYSA-N 2-[2-(2-chloro-4-ethylsulfonylphenoxy)-4-(trifluoromethyl)phenoxy]acetic acid Chemical compound ClC1=CC(S(=O)(=O)CC)=CC=C1OC1=CC(C(F)(F)F)=CC=C1OCC(O)=O JSOMLHMTXRHZQC-UHFFFAOYSA-N 0.000 claims 1
- MCMSVHAYHSAWLW-UHFFFAOYSA-N 2-[2-(2-chloro-4-methylsulfonylanilino)-4-fluorophenoxy]acetic acid Chemical compound ClC1=CC(S(=O)(=O)C)=CC=C1NC1=CC(F)=CC=C1OCC(O)=O MCMSVHAYHSAWLW-UHFFFAOYSA-N 0.000 claims 1
- RREYSGDVUFORPK-UHFFFAOYSA-N 2-[2-[4-(dimethylsulfamoyl)phenoxy]-4-(trifluoromethyl)phenoxy]acetic acid Chemical compound C1=CC(S(=O)(=O)N(C)C)=CC=C1OC1=CC(C(F)(F)F)=CC=C1OCC(O)=O RREYSGDVUFORPK-UHFFFAOYSA-N 0.000 claims 1
- MUYJHGJCOZNEEC-UHFFFAOYSA-N 2-[4-chloro-2-(2-chloro-4-methylsulfonylanilino)phenoxy]acetic acid Chemical compound ClC1=CC(S(=O)(=O)C)=CC=C1NC1=CC(Cl)=CC=C1OCC(O)=O MUYJHGJCOZNEEC-UHFFFAOYSA-N 0.000 claims 1
- JIIYLKVZKUJYCH-UHFFFAOYSA-N 2-[4-chloro-2-(4-ethylsulfonyl-2-methylphenyl)sulfanylphenoxy]acetic acid Chemical compound CC1=CC(S(=O)(=O)CC)=CC=C1SC1=CC(Cl)=CC=C1OCC(O)=O JIIYLKVZKUJYCH-UHFFFAOYSA-N 0.000 claims 1
- VIYPPIJSZFGTOJ-UHFFFAOYSA-N 2-[4-chloro-2-[(3-cyanophenyl)methyl]phenoxy]acetic acid Chemical compound OC(=O)COC1=CC=C(Cl)C=C1CC1=CC=CC(C#N)=C1 VIYPPIJSZFGTOJ-UHFFFAOYSA-N 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 10
- 230000001154 acute effect Effects 0.000 description 7
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 239000002585 base Substances 0.000 description 5
- 230000001684 chronic effect Effects 0.000 description 5
- 239000000543 intermediate Substances 0.000 description 5
- 229910000027 potassium carbonate Inorganic materials 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 4
- 206010016654 Fibrosis Diseases 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 206010047112 Vasculitides Diseases 0.000 description 3
- 206010047115 Vasculitis Diseases 0.000 description 3
- XSCHRSMBECNVNS-UHFFFAOYSA-N benzopyrazine Natural products N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 238000010511 deprotection reaction Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 201000000306 sarcoidosis Diseases 0.000 description 3
- IANQTJSKSUMEQM-UHFFFAOYSA-N 1-benzofuran Chemical compound C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 description 2
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 2
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Chemical compound C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 2
- 208000008035 Back Pain Diseases 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 208000002691 Choroiditis Diseases 0.000 description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 2
- 208000008930 Low Back Pain Diseases 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical group [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 208000003971 Posterior uveitis Diseases 0.000 description 2
- 108050000258 Prostaglandin D receptors Proteins 0.000 description 2
- 102100024218 Prostaglandin D2 receptor 2 Human genes 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- CUFNKYGDVFVPHO-UHFFFAOYSA-N azulene Chemical compound C1=CC=CC2=CC=CC2=C1 CUFNKYGDVFVPHO-UHFFFAOYSA-N 0.000 description 2
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 201000003146 cystitis Diseases 0.000 description 2
- 239000012039 electrophile Substances 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 230000001524 infective effect Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 201000009240 nasopharyngitis Diseases 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- LCPDWSOZIOUXRV-UHFFFAOYSA-N phenoxyacetic acid Chemical class OC(=O)COC1=CC=CC=C1 LCPDWSOZIOUXRV-UHFFFAOYSA-N 0.000 description 2
- 208000023504 respiratory system disease Diseases 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 201000005671 spondyloarthropathy Diseases 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 201000008827 tuberculosis Diseases 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- ZDOUGKHVZLJCRC-YFKPBYRVSA-N (2s)-2-(4-chloro-2-hydroxyphenoxy)propanoic acid Chemical compound OC(=O)[C@H](C)OC1=CC=C(Cl)C=C1O ZDOUGKHVZLJCRC-YFKPBYRVSA-N 0.000 description 1
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 1
- FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical compound N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 description 1
- MBDUIEKYVPVZJH-UHFFFAOYSA-N 1-ethylsulfonylethane Chemical compound CCS(=O)(=O)CC MBDUIEKYVPVZJH-UHFFFAOYSA-N 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
- WIFCOIJZOLSVTK-UHFFFAOYSA-N 2-(2-chloro-4-methylsulfonylphenyl)sulfanyl-4-fluorophenol Chemical compound ClC1=CC(S(=O)(=O)C)=CC=C1SC1=CC(F)=CC=C1O WIFCOIJZOLSVTK-UHFFFAOYSA-N 0.000 description 1
- JCOOEANWCIRNTR-UHFFFAOYSA-N 2-(4-fluoro-2-hydroxyphenoxy)-2-methylpropanoic acid Chemical compound OC(=O)C(C)(C)OC1=CC=C(F)C=C1O JCOOEANWCIRNTR-UHFFFAOYSA-N 0.000 description 1
- CVCUSGPSZYITAD-UHFFFAOYSA-N 2-[2-[4-(dimethylsulfamoyl)phenyl]sulfanyl-4-(trifluoromethyl)phenoxy]acetic acid Chemical compound C1=CC(S(=O)(=O)N(C)C)=CC=C1SC1=CC(C(F)(F)F)=CC=C1OCC(O)=O CVCUSGPSZYITAD-UHFFFAOYSA-N 0.000 description 1
- IEACYKMVFGVBLH-UHFFFAOYSA-N 2-[4-chloro-2-(4-ethylsulfonylphenoxy)phenoxy]acetic acid Chemical compound C1=CC(S(=O)(=O)CC)=CC=C1OC1=CC(Cl)=CC=C1OCC(O)=O IEACYKMVFGVBLH-UHFFFAOYSA-N 0.000 description 1
- QJUXXQFUEROZHT-UHFFFAOYSA-N 2-chloro-1-fluoro-4-methylsulfonylbenzene Chemical compound CS(=O)(=O)C1=CC=C(F)C(Cl)=C1 QJUXXQFUEROZHT-UHFFFAOYSA-N 0.000 description 1
- URGBWNNXMJCAOC-UHFFFAOYSA-N 4-chloro-2-(2-chloro-4-ethylsulfonylanilino)phenol Chemical compound ClC1=CC(S(=O)(=O)CC)=CC=C1NC1=CC(Cl)=CC=C1O URGBWNNXMJCAOC-UHFFFAOYSA-N 0.000 description 1
- RLWNBVYQQPYTPY-UHFFFAOYSA-N 4-chloro-2-(2-chloro-4-ethylsulfonylphenoxy)phenol Chemical compound ClC1=CC(S(=O)(=O)CC)=CC=C1OC1=CC(Cl)=CC=C1O RLWNBVYQQPYTPY-UHFFFAOYSA-N 0.000 description 1
- GDRVFDDBLLKWRI-UHFFFAOYSA-N 4H-quinolizine Chemical compound C1=CC=CN2CC=CC=C21 GDRVFDDBLLKWRI-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010000748 Acute febrile neutrophilic dermatosis Diseases 0.000 description 1
- 208000032671 Allergic granulomatous angiitis Diseases 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 208000035939 Alveolitis allergic Diseases 0.000 description 1
- 208000028185 Angioedema Diseases 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 206010053555 Arthritis bacterial Diseases 0.000 description 1
- 206010003267 Arthritis reactive Diseases 0.000 description 1
- 201000002909 Aspergillosis Diseases 0.000 description 1
- 208000036641 Aspergillus infections Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000006344 Churg-Strauss Syndrome Diseases 0.000 description 1
- XXAXVMUWHZHZMJ-UHFFFAOYSA-N Chymopapain Chemical compound OC1=CC(S(O)(=O)=O)=CC(S(O)(=O)=O)=C1O XXAXVMUWHZHZMJ-UHFFFAOYSA-N 0.000 description 1
- 108090001069 Chymopapain Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 208000015943 Coeliac disease Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000009248 Congenital Hip Dislocation Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 108010091326 Cryoglobulins Proteins 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 206010012468 Dermatitis herpetiformis Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 208000006926 Discoid Lupus Erythematosus Diseases 0.000 description 1
- 208000019872 Drug Eruptions Diseases 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 206010014950 Eosinophilia Diseases 0.000 description 1
- 206010065563 Eosinophilic bronchitis Diseases 0.000 description 1
- 208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 description 1
- 206010014989 Epidermolysis bullosa Diseases 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 206010015218 Erythema multiforme Diseases 0.000 description 1
- 208000027445 Farmer Lung Diseases 0.000 description 1
- 208000032678 Fixed drug eruption Diseases 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 208000007465 Giant cell arteritis Diseases 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 208000005232 Glossitis Diseases 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 208000003695 Histiocytic Necrotizing Lymphadenitis Diseases 0.000 description 1
- 206010069070 Histiocytic necrotising lymphadenitis Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 1
- 201000003838 Idiopathic interstitial pneumonia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000004575 Infectious Arthritis Diseases 0.000 description 1
- 206010022941 Iridocyclitis Diseases 0.000 description 1
- 208000028257 Joubert syndrome with oculorenal defect Diseases 0.000 description 1
- 208000003456 Juvenile Arthritis Diseases 0.000 description 1
- 208000015282 Kikuchi-Fujimoto disease Diseases 0.000 description 1
- 206010024434 Lichen sclerosus Diseases 0.000 description 1
- 201000003088 Limited Scleroderma Diseases 0.000 description 1
- 208000024140 Limited cutaneous systemic sclerosis Diseases 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M Methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 238000006751 Mitsunobu reaction Methods 0.000 description 1
- 208000003250 Mixed connective tissue disease Diseases 0.000 description 1
- 201000002795 Muckle-Wells syndrome Diseases 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 201000009623 Myopathy Diseases 0.000 description 1
- 201000002481 Myositis Diseases 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 206010028735 Nasal congestion Diseases 0.000 description 1
- 206010028836 Neck pain Diseases 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 206010030216 Oesophagitis Diseases 0.000 description 1
- 241001420836 Ophthalmitis Species 0.000 description 1
- 102000016978 Orphan receptors Human genes 0.000 description 1
- 108070000031 Orphan receptors Proteins 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 108010064255 Paraproteins Proteins 0.000 description 1
- 102000015094 Paraproteins Human genes 0.000 description 1
- 206010034277 Pemphigoid Diseases 0.000 description 1
- 241000721454 Pemphigus Species 0.000 description 1
- 208000004362 Penile Induration Diseases 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 208000020758 Peyronie disease Diseases 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010036774 Proctitis Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 208000002200 Respiratory Hypersensitivity Diseases 0.000 description 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 1
- 206010039094 Rhinitis perennial Diseases 0.000 description 1
- 208000036284 Rhinitis seasonal Diseases 0.000 description 1
- 208000007893 Salpingitis Diseases 0.000 description 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 201000002661 Spondylitis Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 208000010265 Sweet syndrome Diseases 0.000 description 1
- 206010042742 Sympathetic ophthalmia Diseases 0.000 description 1
- 201000009594 Systemic Scleroderma Diseases 0.000 description 1
- 206010042953 Systemic sclerosis Diseases 0.000 description 1
- 208000001106 Takayasu Arteritis Diseases 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010057970 Toxic skin eruption Diseases 0.000 description 1
- 208000034327 Tumor necrosis factor receptor 1 associated periodic syndrome Diseases 0.000 description 1
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 208000025851 Undifferentiated connective tissue disease Diseases 0.000 description 1
- 208000017379 Undifferentiated connective tissue syndrome Diseases 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 208000035222 X-linked skeletal dysplasia-intellectual disability syndrome Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000010085 airway hyperresponsiveness Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 208000002205 allergic conjunctivitis Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 208000004631 alopecia areata Diseases 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 206010068168 androgenetic alopecia Diseases 0.000 description 1
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 201000004612 anterior uveitis Diseases 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 229910052586 apatite Inorganic materials 0.000 description 1
- 208000024998 atopic conjunctivitis Diseases 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 201000003308 autosomal dominant familial periodic fever Diseases 0.000 description 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 208000010217 blepharitis Diseases 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 201000009267 bronchiectasis Diseases 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 229960002023 chloroprocaine Drugs 0.000 description 1
- 201000001352 cholecystitis Diseases 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 208000002849 chondrocalcinosis Diseases 0.000 description 1
- 208000013116 chronic cough Diseases 0.000 description 1
- 201000009151 chronic rhinitis Diseases 0.000 description 1
- WCZVZNOTHYJIEI-UHFFFAOYSA-N cinnoline Chemical compound N1=NC=CC2=CC=CC=C21 WCZVZNOTHYJIEI-UHFFFAOYSA-N 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 208000022993 cryopyrin-associated periodic syndrome Diseases 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 208000004921 cutaneous lupus erythematosus Diseases 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 208000014906 developmental dysplasia of the hip Diseases 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 201000001564 eosinophilic gastroenteritis Diseases 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 1
- 125000006125 ethylsulfonyl group Chemical group 0.000 description 1
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 description 1
- 208000022195 farmer lung disease Diseases 0.000 description 1
- 208000012587 fixed pigmented erythema Diseases 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 description 1
- 230000000642 iatrogenic effect Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- HOBCFUWDNJPFHB-UHFFFAOYSA-N indolizine Chemical compound C1=CC=CN2C=CC=C21 HOBCFUWDNJPFHB-UHFFFAOYSA-N 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 1
- 201000006334 interstitial nephritis Diseases 0.000 description 1
- 201000004614 iritis Diseases 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 229960004592 isopropanol Drugs 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 201000011486 lichen planus Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 125000003564 m-cyanobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(C#N)=C1[H])C([H])([H])* 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 208000008585 mastocytosis Diseases 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 206010063344 microscopic polyangiitis Diseases 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 208000005963 oophoritis Diseases 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 125000002524 organometallic group Chemical group 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 208000010403 panophthalmitis Diseases 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- VSIIXMUUUJUKCM-UHFFFAOYSA-D pentacalcium;fluoride;triphosphate Chemical compound [F-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O VSIIXMUUUJUKCM-UHFFFAOYSA-D 0.000 description 1
- 208000022719 perennial allergic rhinitis Diseases 0.000 description 1
- 201000001245 periodontitis Diseases 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 208000017983 photosensitivity disease Diseases 0.000 description 1
- LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical compound C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 description 1
- 201000006292 polyarteritis nodosa Diseases 0.000 description 1
- 208000005987 polymyositis Diseases 0.000 description 1
- 208000015768 polyposis Diseases 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- BHMBVRSPMRCCGG-OUTUXVNYSA-N prostaglandin D2 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](C\C=C/CCCC(O)=O)[C@@H](O)CC1=O BHMBVRSPMRCCGG-OUTUXVNYSA-N 0.000 description 1
- BHMBVRSPMRCCGG-UHFFFAOYSA-N prostaglandine D2 Natural products CCCCCC(O)C=CC1C(CC=CCCCC(O)=O)C(O)CC1=O BHMBVRSPMRCCGG-UHFFFAOYSA-N 0.000 description 1
- 201000007094 prostatitis Diseases 0.000 description 1
- CPNGPNLZQNNVQM-UHFFFAOYSA-N pteridine Chemical compound N1=CN=CC2=NC=CN=C21 CPNGPNLZQNNVQM-UHFFFAOYSA-N 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 208000002815 pulmonary hypertension Diseases 0.000 description 1
- 208000009954 pyoderma gangrenosum Diseases 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 1
- 208000002574 reactive arthritis Diseases 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 208000017022 seasonal allergic rhinitis Diseases 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 201000001223 septic arthritis Diseases 0.000 description 1
- 208000025869 skeletal dysplasia-intellectual disability syndrome Diseases 0.000 description 1
- 201000008261 skin carcinoma Diseases 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 230000008409 synovial inflammation Effects 0.000 description 1
- 201000004595 synovitis Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 206010043207 temporal arteritis Diseases 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 230000005951 type IV hypersensitivity Effects 0.000 description 1
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 208000000143 urethritis Diseases 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 230000003156 vasculitic effect Effects 0.000 description 1
- 208000001319 vasomotor rhinitis Diseases 0.000 description 1
- 208000010484 vulvovaginitis Diseases 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0302281A SE0302281D0 (sv) | 2003-08-21 | 2003-08-21 | Novel compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200601485B true ZA200601485B (en) | 2007-11-28 |
Family
ID=28450292
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200601485A ZA200601485B (en) | 2003-08-21 | 2006-02-20 | Phenoxiacetic acid derivatives |
Country Status (5)
| Country | Link |
|---|---|
| CN (1) | CN1845894B (sv) |
| NO (1) | NO20061290L (sv) |
| SE (1) | SE0302281D0 (sv) |
| UA (1) | UA86773C2 (sv) |
| ZA (1) | ZA200601485B (sv) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103539760B (zh) * | 2013-10-23 | 2016-04-13 | 东南大学 | 苯氧苯乙酸类内皮素拮抗剂及其制备方法与应用 |
| CN104788369B (zh) * | 2015-03-17 | 2017-06-06 | 三峡大学 | 双吡啶基苯氧基脂肪酰胺衍生物及其医药用途 |
| CN104817539B (zh) * | 2015-03-17 | 2017-06-09 | 三峡大学 | 2‑苯氧基喹喔啉衍生物及其医药用途 |
| CN104817491B (zh) * | 2015-03-17 | 2017-06-06 | 三峡大学 | N‑吡啶基‑2‑苯氧基脂肪酰胺及其医药用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH432119A (de) * | 1963-02-22 | 1967-03-15 | Geigy Ag J R | Verwendung von Halogen-o-hydroxy-diphenyläthern als antimikrobielle Mittel |
| JPS5239888B2 (sv) * | 1973-05-28 | 1977-10-07 | ||
| CH582476A5 (sv) * | 1973-10-29 | 1976-12-15 | Ciba Geigy Ag | |
| GB1585963A (en) * | 1976-10-14 | 1981-03-11 | Lilly Industries Ltd | Aryl sulphur compounds |
| JPS5951943B2 (ja) * | 1978-08-21 | 1984-12-17 | キツセイ薬品工業株式会社 | 新規なイミダゾ−ル誘導体 |
| AU2003211427A1 (en) * | 2002-02-18 | 2003-09-04 | Ishihara Sangyo Kaisha, Ltd. | Pyridine derivatives or salts thereof and cytokine production inhibitors containing the same |
-
2003
- 2003-08-21 SE SE0302281A patent/SE0302281D0/sv unknown
-
2004
- 2004-08-18 UA UAA200601339A patent/UA86773C2/ru unknown
- 2004-08-18 CN CN2004800250035A patent/CN1845894B/zh not_active Expired - Fee Related
-
2006
- 2006-02-20 ZA ZA200601485A patent/ZA200601485B/en unknown
- 2006-03-21 NO NO20061290A patent/NO20061290L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| UA86773C2 (en) | 2009-05-25 |
| CN1845894B (zh) | 2010-07-07 |
| CN1845894A (zh) | 2006-10-11 |
| NO20061290L (no) | 2006-05-22 |
| SE0302281D0 (sv) | 2003-08-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8003703B2 (en) | Phenoxiacetic acid derivatives | |
| RU2457204C2 (ru) | Цианоизохинолиновые соединения (варианты), фармацевтическая композиция на их основе, способ ингибирования активности гидроксилазы гипоксия-индуцибельного фактора (hif) и способ лечения и/или профилактики состояния, связанного с hif, и/или состояния, связанного с эритропоэтином, и/или анемии | |
| EP1984360B1 (en) | Compounds and methods for modulating FX-receptors | |
| ES2362788T3 (es) | Compuesto de indolina y proceso para la producción del mismo. | |
| ZA200508088B (en) | Novel compounds | |
| EP1513812B1 (en) | Substituted indoles | |
| US8148572B2 (en) | Compounds | |
| AU2004242624B2 (en) | Novel substituted 3-sulfur indoles | |
| CA3105657A1 (en) | Pyridine carboxamide compounds for inhibiting nav1.8 | |
| JP2007502806A5 (sv) | ||
| JP2007262009A (ja) | ヘテロアリール低級カルボン酸誘導体 | |
| JP4915715B2 (ja) | フェニルピリダジン誘導体及びこれを含有する医薬 | |
| AU2007275931A1 (en) | Novel tricyclic spiropiperidine compounds, their synthesis and their uses as modulators of chemokine receptor activity | |
| US20130079313A1 (en) | Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors | |
| JP2012509309A (ja) | Ｆａａｈ阻害剤としての１−オキサ−８−アザスピロ［４．５］デカン−８−カルボキサミド化合物 | |
| BRPI0710469A2 (pt) | composto, composição farmacêutica, e, intermediário | |
| NZ567070A (en) | Biphenyloxyacetic acid derivatives for the treatment of respiratory disease | |
| AU2008212673A1 (en) | Napadisylate salt of a muscarinic M3 antagonist | |
| ZA200601485B (en) | Phenoxiacetic acid derivatives | |
| TW201434817A (zh) | 新穎化合物 | |
| EP2855450A1 (en) | Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors | |
| JP2011518146A (ja) | Ｆａａｈ阻害剤として有用な４−［３−（アリールオキシ）ベンジリデン］−３−メチルピペリジンアリールカルボキサミド化合物 | |
| WO1997009306A1 (fr) | Nouveaux derives d'isothio-uree | |
| JPS6364408B2 (sv) | ||
| JP2013540780A (ja) | イミダゾール誘導体並びにその製造法及び使用 |